Biogen’s multiple sclerosis franchise has been handed a boost with the US approval of Vumerity, a follow-up to its blockbuster Tecfidera that ... Vumerity (diroximel fumarate) for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback